Core Viewpoint - Gilead Sciences (GILD.US) shares rose over 5% to a record high of $155.54 following the release of its financial results, indicating strong performance and growth potential in the market [1] Financial Performance - For the full year 2025, Gilead reported total revenue of $29.443 billion, representing a year-over-year increase of 2.4% [1] - The net profit attributable to the company was $8.51 billion, showing a significant year-over-year increase of approximately 16.73 times [1] - Non-GAAP diluted earnings per share reached $8.15, reflecting a substantial year-over-year growth of 77% [1] Product Development and Market Position - Gilead's Chairman and CEO, Daniel O'Day, highlighted that the previous year was fruitful for the company, marked by the successful launch of Yeztugo, the world's first semi-annual HIV prevention therapy [1] - The continued growth of Biktarvy and Descovy has established a solid foundation for the company's future growth [1]

Core Viewpoint - Gilead Sciences (GILD.US) shares rose by 5.8%, reaching a historical high of $155.75 following the release of its Q4 earnings report, which exceeded analyst expectations [1] Financial Performance - The company reported Q4 revenue of $7.9 billion, a 5% year-over-year increase, surpassing analyst expectations of $7.7 billion [1] - Adjusted earnings per share (EPS) were $1.86, exceeding the forecast of $1.81 [1] Product Sales - Sales of HIV-related products increased by 6% year-over-year to $5.8 billion, driven primarily by rising demand for prevention and treatment [1]

Core Viewpoint - Gilead Sciences Inc. reported strong fourth-quarter earnings but provided weak guidance for fiscal 2026, leading to a decline in share price [1][2]. Financial Performance - Gilead reported quarterly earnings of $1.86 per share, exceeding the consensus estimate of $1.81 [1]. - Quarterly revenue reached $7.93 billion, surpassing the Street estimate of $7.69 billion [1]. Future Guidance - For fiscal 2026, Gilead expects adjusted EPS in the range of $8.45 to $8.85, compared to the analyst estimate of $8.74 [2]. - Revenue guidance for fiscal 2026 is projected between $29.6 billion and $30 billion, below the analyst estimate of $30.22 billion [2]. Analyst Ratings and Price Targets - Needham analyst Joseph Stringer maintained a Buy rating and raised the price target from $140 to $170 [4]. - Scotiabank analyst Louis Chen maintained a Sector Outperform rating and increased the price target from $140 to $177 [4]. - Cantor Fitzgerald analyst Carter Gould maintained an Overweight rating and raised the price target from $135 to $155 [4]. Market Reaction - Following the earnings announcement and guidance, Gilead shares fell 1.8% to $144.55 in pre-market trading [2].

Group 1 - BMW is recalling hundreds of thousands of cars, as reported by the newspaper Bild, citing the German premium carmaker [1]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Group 1 - Morgan Stanley raised the target price for Gilead Sciences from $150 to $160 [1]

Core Viewpoint - Gilead Sciences reported a 5% year-over-year revenue growth in Q4, reaching $7.9 billion, surpassing analyst expectations of $7.7 billion [1] - The adjusted earnings per share (EPS) of $1.86 also exceeded the forecast of $1.81 [1] Group 1: Financial Performance - Q4 revenue increased by 5% to $7.9 billion, exceeding analyst expectations [1] - Adjusted EPS was $1.86, higher than the anticipated $1.81 [1] - Sales of HIV-related products rose by 6% to $5.8 billion, driven by increased demand for prevention and treatment [1] - Sales of Remdesivir declined by 37% to $212 million, primarily due to a decrease in COVID-19 related hospitalizations [1] Group 2: Future Outlook - Gilead expects product sales to range between $29.6 billion and $30 billion for the year [1] - The adjusted EPS guidance is projected to be between $8.45 and $8.85, while analysts expect $30.2 billion and $8.75 respectively [1] - The guidance is influenced by a pricing agreement with the Trump administration and uncertainties following the expiration of certain government subsidies [1]

Group 1 - Gilead Sciences (GILD.US) experienced a decline of 1.8% in after-hours trading, closing at $144.55 [1]

Core Viewpoint - Gilead Sciences reported a 5% year-over-year revenue growth in Q4, reaching $7.9 billion, surpassing analyst expectations of $7.7 billion [1] - The adjusted earnings per share (EPS) were $1.86, exceeding the forecast of $1.81 [1] Financial Performance - Q4 revenue increased to $7.9 billion, up from the previous year [1] - Sales of HIV-related products rose by 6% to $5.8 billion, driven by increased demand for prevention and treatment [1] - Sales of Remdesivir declined by 37% to $212 million, primarily due to a decrease in COVID-19 related hospitalizations [1] Future Outlook - Gilead expects product sales to range between $29.6 billion and $30 billion for the year [1] - The adjusted EPS guidance is projected to be between $8.45 and $8.85, while analysts expect $30.2 billion and $8.75 respectively [1] - The guidance is influenced by a pricing agreement with the Trump administration and uncertainties following the expiration of certain government subsidies [1]

Core Insights - Gilead Sciences reported $7.93 billion in revenue for Q4 2025, a year-over-year increase of 4.7% and a surprise of +4.63% over the Zacks Consensus Estimate of $7.57 billion [1] - The EPS for the same period was $1.86, slightly down from $1.90 a year ago, with an EPS surprise of +1.91% compared to the consensus estimate of $1.83 [1] Financial Performance - Total product sales in the U.S. reached $5.87 billion, exceeding the average estimate of $5.59 billion, representing a year-over-year change of +5.8% [4] - Total product sales globally were reported at $7.9 billion, surpassing the six-analyst average estimate of $7.53 billion, with a year-over-year change of +4.9% [4] - Royalty contract and other revenues were $22 million, below the average estimate of $38.66 million, reflecting a year-over-year decline of -33.3% [4] Product Sales Breakdown - Product sales for Liver Disease (Other) in the U.S. were $168 million, significantly above the average estimate of $141.36 million, marking a year-over-year increase of +189.7% [4] - Sales for HIV product Biktarvy totaled $3.97 billion, exceeding the average estimate of $3.79 billion, with a year-over-year change of +5.1% [4] - Sales for Veklury were $212 million, below the average estimate of $266.85 million, indicating a year-over-year decline of -37.1% [4] Stock Performance - Gilead's shares have returned +23.7% over the past month, while the Zacks S&P 500 composite showed no change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]